var data={"title":"Atovaquone: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Atovaquone: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5679?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=atovaquone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Atovaquone: Patient drug information&quot;</a> and <a href=\"topic.htm?path=atovaquone-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Atovaquone: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137522\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Mepron</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137523\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Mepron</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137550\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiprotozoal</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137526\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <b>\n          <i>Pneumocystis jirovecii</i></b> pneumonia (PCP), prevention:</b> Oral: 1,500 mg once daily with food</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>PCP, mild to moderate, treatment:</b> Oral: 750 mg twice daily with food for 21 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Babesiosis (off-label use):</b> Oral: 750 mg twice daily with azithromycin for at least 7 to 10 days; <b>Note:</b> Relapsing infection may require at least 6 weeks of therapy (Krauss 2000; Vannier 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Toxoplasma gondii</i> encephalitis in HIV-infected patients (off-label use; alternative agent) (HHS [OI adult 2017]):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prophylaxis: 1,500 mg once daily with food (either as monotherapy or with pyrimethamine plus leucovorin); primary prophylaxis is indicated for Toxoplasma IgG-positive patients with CD4 count &lt;100 cells/mm<sup>3</sup>. Continue primary prophylaxis following initiation of ART until CD4 count &gt;200 cells/mm<sup>3</sup> for &gt;3 months; some experts discontinue primary prophylaxis in patients with a CD4 count between 100 to 200 cells/mm<sup>3</sup> who are receiving ART and have had an undetectable viral load for &ge;3 to 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment: 1,500 mg twice daily with food (either with pyrimethamine plus leucovorin, or with sulfadiazine, or as monotherapy) for at least 6 weeks (longer if extensive disease or incomplete response)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Secondary prophylaxis (chronic maintenance): 750 to 1,500 mg twice daily with food (either with pyrimethamine plus leucovorin, or with sulfadiazine, or as monotherapy); may discontinue when asymptomatic and CD4 count &gt;200 cells/mm<sup>3</sup> for &gt;6 months in response to antiretrovirals</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137540\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=atovaquone-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Atovaquone: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Pneumocystis jirovecii</i> pneumonia (PCP), prevention: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children &lt;13 years (off-label use) (CDC 2009): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1 to 3 months: 30 mg/kg once daily with food</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">4 to 24 months: 45 mg/kg once daily with food</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;24 months: 30 mg/kg once daily with food</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents &ge;13 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>PCP, mild to moderate, treatment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children &lt;13 years (off-label use) (CDC 2009): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Birth to 3 months: 30 to 40 mg/kg/day in 2 divided doses with food (maximum: 1,500 mg daily)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">3 to 24 months: 45 mg/kg/day in 2 divided doses with food (maximum: 1,500 mg daily)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;24 months: 30 to 40 mg/kg/day in 2 divided doses with food (maximum: 1,500 mg daily)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents &ge;13 years: Refer to adult dosing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Toxoplasma gondii</i> encephalitis in HIV-exposed/infected patients (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children &lt;13 years: Prophylaxis (either as monotherapy or with pyrimethamine plus leucovorin) (CDC 2009): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1 to 3 months: 30 mg/kg once daily with food</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">4 to 24 months: 45 mg/kg once daily with food</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;24 months: 30 mg/kg once daily with food</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents: Primary prophylaxis, treatment, and secondary prophylaxis (chronic maintenance) (HHS [OI adult 2017]): Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Babesiosis (off-label use):</b> Children: Oral: 40 mg/kg/day in 2 divided doses with azithromycin for at least 7 to 10 days (maximum: 1,500 mg daily). <b>Note:</b> Relapsing infection may require at least 6 weeks of therapy (Vannier 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137527\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15673223\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied). However, atovaquone is not appreciably renally excreted.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15673224\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied). Atovaquone undergoes enterohepatic cycling and primarily hepatic excretion. Use caution in patients with severe impairment; monitor closely.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137504\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mepron: 750 mg/5 mL (5 mL, 210 mL) [contains benzyl alcohol; citrus flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 750 mg/5 mL (210 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137491\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6265261\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Must administer with food. Shake suspension gently before use. Once opened, a foil pouch can be emptied on a dosing spoon, in a cup, or directly into the mouth.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137505\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Pneumocystis jirovecii</i> pneumonia (PCP), prophylaxis: Prevention of PCP in adults and adolescents 13 years and older who are intolerant to trimethoprim-sulfamethoxazole (TMP-SMZ)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Pneumocystis jirovecii </i>pneumonia (PCP), treatment: Acute oral treatment of mild to moderate PCP in adults and adolescents 13 years and older who are intolerant to TMP-SMZ</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475144\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Babesiosis; Toxoplasma gondii encephalitis (prophylaxis/treatment/chronic maintenance) in HIV-infected patients (adolescents and adults); Toxoplasma gondii encephalitis (prophylaxis) in HIV-exposed/infected patients (children)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137498\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not always defined. Adverse reaction statistics have been compiled from studies including patients with advanced HIV disease. Consequently, it is difficult to distinguish reactions attributed to atovaquone from those caused by the underlying disease or a combination thereof.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (16% to 31%), insomnia (10% to 19%), depression, pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (22% to 46%), pruritus (5% to &ge;10%), diaphoresis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (19% to 42%), nausea (21% to 32%), vomiting (14% to 22%), abdominal pain (4% to 21%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (18% to 22%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (8% to 31%), myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (14% to 25%), rhinitis (5% to 24%), dyspnea (15% to 21%), sinusitis (7% to &ge;10%), flu-like symptoms</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (14% to 40%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (3% to 8%), anxiety (&le;7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hyponatremia (7% to 10%), hyperglycemia (&le;9%), increased amylase (7% to 8%), hypoglycemia (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Oral candidiasis (5% to 10%), anorexia (&le;7%), dyspepsia (&le;5%), constipation (&le;3%), dysgeusia (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (4% to 6%), neutropenia (3% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased liver enzymes (4% to 8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased blood urea nitrogen (&le;1%), increased serum creatinine (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Bronchospasm (2% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acute renal failure, angioedema, constriction of the pharynx, corneal disease (vortex keratopathy), desquamation, erythema multiforme, hepatic failure (rare), hepatitis (rare), hypersensitivity reaction, methemoglobinemia, pancreatitis, Stevens-Johnson syndrome, thrombocytopenia, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137509\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to atovaquone or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137495\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diarrhea/vomiting: Absorption may be decreased in patients who have diarrhea or vomiting; monitor closely and consider use of an antiemetic. If severe, consider use of an alternative antiprotozoal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions (eg, angioedema, bronchospasm, throat tightness, urticaria) have occurred.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal disorders: Consider parenteral therapy with alternative agents in patients who have difficulty taking atovaquone with food. Gastrointestinal disorders may limit absorption of oral medications; may not achieve adequate plasma levels.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment; monitor closely; rare cases of cholestatic hepatitis, elevated liver function tests, and fatal liver failure have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; <i>Pneumocystis jirovecii</i> pneumonia (PCP): Appropriate use: When used for treatment, has only been indicated in mild to moderate PCP; not studied for use in severe PCP; atovaquone has less adverse effects than trimethoprim-sulfamethoxazole (TMP-SMZ) (the treatment of choice for mild to moderate PCP), although atovaquone is less effective than TMP-SMZ (HHS [OI adult 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in elderly patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298792\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137499\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8957&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: May decrease the serum concentration of Atovaquone. Management: Consider alternatives to the use of atovaquone with efavirenz when possible.  If this combination must be used, monitor for evidence of reduced atovaquone clinical effectiveness.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etoposide: Atovaquone may increase the serum concentration of Etoposide.  Management: Consider separating the administration of atovaquone and etoposide by at least 1 to 2 days.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etoposide Phosphate: Atovaquone may increase the serum concentration of Etoposide Phosphate.  Management: Consider separating the administration of atovaquone and etoposide by at least 1 to 2 days.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indinavir: Atovaquone may decrease the serum concentration of Indinavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: May decrease the serum concentration of Atovaquone. Management: Consider alternatives to metoclopramide when possible; atovaquone should only be used with metoclopramide if no other antiemetics are available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May decrease the serum concentration of Atovaquone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May decrease the serum concentration of Atovaquone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracycline: May decrease the serum concentration of Atovaquone.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137519\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Ingestion with a fatty meal increases absorption. Management: Administer with food, preferably high-fat meals (peanuts or ice cream).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137501\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6264005\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Diagnosis and treatment of <i>Pneumocystis jirovecii</i> pneumonia (PCP) in pregnant women is the same as in nonpregnant women; however, information specific to the use of atovaquone in pregnancy is limited (HHS [OI adult 2015]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20472581\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if atovaquone is excreted in breast milk. The manufacturer recommends that caution be exercised when administering atovaquone to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6265260\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Must be taken with food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20472638\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Hepatic function at baseline (monitor closely during treatment in patients with severe hepatic impairment), hypersensitivity reactions, CD4 count (for chronic maintenance treatment in toxoplasmosis), patient&rsquo;s food tolerance/ability to take atovaquone, post-dose vomiting, diarrhea</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137494\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits electron transport in mitochondria resulting in the inhibition of key metabolic enzymes responsible for the synthesis of nucleic acids and ATP</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137508\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants and Children &lt;2 years of age: Decreased absorption</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Oral suspension: Absorption is enhanced 1.4-fold with food; decreased absorption with single doses exceeding 750 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>dss</sub>: 0.6 &plusmn; 0.17 L/kg; CSF concentration is &lt;1% of the plasma concentration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &gt;99%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Undergoes enterohepatic recirculation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Suspension (administered with food): 47% &plusmn; 15%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children (4 months to 12 years): 60 hours (range: 31 to 163 hours) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 2.9 days </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults with AIDS: 2.2 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Dual peak serum concentrations at 1 to 8 hours and at 24 to 96 hours after dose due to enterohepatic cycling </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (&gt;94% as unchanged drug); urine (&lt;1%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6884404\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Atovaquone Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg/5 mL (210 mL): $1,378.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Mepron Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg/5 mL (5 mL): $39.79</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038533\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Mepron (BB, BM, BS, BZ, GY, JM, PL, SR, TT);</li>\n      <li>Samtirel (JP);</li>\n      <li>Wellvone (AT, AU, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, NL, PT, SE, SI, ZA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atovaquone-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Artymowicz RJ and James VE, &ldquo;Atovaquone: A New Antipneumocystis Agent,&rdquo; <i>Clin Pharm</i>, 1993, 12(8):563-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atovaquone-drug-information/abstract-text/8222520/pubmed\" target=\"_blank\" id=\"8222520\">8222520</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Behbahani R, Moshfeghi M, and Baxter JD, &ldquo;Therapeutic Approaches for AIDS-Related Toxoplasmosis,&rdquo; <i>Ann Pharmacother</i>, 1995, 29(7-8):760-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atovaquone-drug-information/abstract-text/8520094/pubmed\" target=\"_blank\" id=\"8520094\">8520094</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atovaquone-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    El-Sadr WM, Murphy RL, Yurik TM, et al, &ldquo;Atovaquone Compared With Dapsone for the Prevention of <i>Pneumocystis carinii</i> in Patients With HIV Infection Who Cannot Tolerate Trimethoprim, Sulfonamides, or Both,&rdquo; <i>N Engl J Med</i>, 1998, 339(26):1889-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atovaquone-drug-information/abstract-text/9862944/pubmed\" target=\"_blank\" id=\"9862944\">9862944</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haile LG and Flaherty JF, &ldquo;Atovaquone: A Review,&rdquo; <i>Ann Pharmacother</i>, 1993, 27(12):1488-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atovaquone-drug-information/abstract-text/8305784/pubmed\" target=\"_blank\" id=\"8305784\">8305784</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. November 2013. <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. July 2017. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed March 8, 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hughes W, Leoung G, Kramer F, et al, &ldquo;Comparison of Atovaquone (566C80) With Trimethoprim-Sulfamethoxazole to Treat <i>Pneumocystis carinii</i> Pneumonia in Patients With AIDS,&rdquo; <i>N Engl J Med</i>, 1993, 328(21):1521-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atovaquone-drug-information/abstract-text/8479489/pubmed\" target=\"_blank\" id=\"8479489\">8479489</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atovaquone-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Katlama C, Mouthon B, Gourdon D, et al, &ldquo;Atovaquone as Long-term Suppressive Therapy for Toxoplasmic Encephalitis in Patients With AIDS and Multiple Drug Intolerance. Atovaquone Expanded Access Group,&rdquo; <i>AIDS</i>, 1996, 10(10):1107-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atovaquone-drug-information/abstract-text/8874627/pubmed\" target=\"_blank\" id=\"8874627\">8874627</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11078770\"></a>Krause PJ, Lepore T, Sikand VK, et al. Atovaquone and azithromycin for the treatment of babesiosis. <i>N Engl J Med</i>. 2000;343:1454-1458.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atovaquone-drug-information/abstract-text/11078770/pubmed\" target=\"_blank\" id=\"11078770\">11078770</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mepron (atovaquone) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pagano G, Kennedy W, Weller S, et al, &ldquo;The Safety and Pharmacokinetics of Atovaquone in Immunocompromised Children,&rdquo; Abstracts of the IX International Conference on AIDS in Affiliation With the IV STD World Congress: Berlin, 1993, June 6-11; Abs No PO-B10-1455.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spencer CM and Goa KL, &ldquo;Atovaquone. A Review of Its Pharmacological Properties and Therapeutic Efficacy in Opportunistic Infections,&rdquo; <i>Drugs</i>, 1995, 50(1):176-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atovaquone-drug-information/abstract-text/7588086/pubmed\" target=\"_blank\" id=\"7588086\">7588086</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22716978\"></a>Vannier E and Krause PJ, &ldquo;Human Babesiosis,&rdquo; <i>N Engl J Med</i>, 2012, 366(25):2397-2407.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atovaquone-drug-information/abstract-text/22716978/pubmed\" target=\"_blank\" id=\"22716978\">22716978</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8957 Version 118.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F137522\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F137523\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F137550\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F137526\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F137540\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F137527\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15673223\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15673224\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F137504\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F137491\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F6265261\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F137505\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475144\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F137498\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F137509\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F137495\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298792\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F137499\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F137519\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F137501\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6264005\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20472581\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F6265260\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F20472638\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F137494\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F137508\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F6884404\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038533\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8957|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=atovaquone-patient-drug-information\" class=\"drug drug_patient\">Atovaquone: Patient drug information</a></li><li><a href=\"topic.htm?path=atovaquone-pediatric-drug-information\" class=\"drug drug_pediatric\">Atovaquone: Pediatric drug information</a></li></ul></div></div>","javascript":null}